6:04 PM
 | 
Aug 29, 2012
 |  BC Extra  |  Company News

FDA issues notice about Kalydeco safety concern

FDA issued a notice about the potential for cataract development in children receiving cystic fibrosis drug Kalydeco ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) based on the results of an animal study. The agency said cataracts were...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >